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Triage After Hospitalization
With Advanced Heart Failure
The ESCAPE (Evaluation Study of
Congestive Heart Failure and Pulmonary Artery
Catheterization Effectiveness) Risk Model and Discharge Score
Christopher M. O’Connor, MD,* Vic Hasselblad, PHD,* Rajendra H. Mehta, MD, MS,*
Gudaye Tasissa, PHD,* Robert M. Califf, MD,* Mona Fiuzat, PHARMD,* Joseph G. Rogers, MD,*
Carl V. Leier, MD,† Lynne W. Stevenson, MD‡
Durham, North Carolina; Columbus, Ohio; and Boston, Massachusetts
Objectives Identifying high-risk heart failure (HF) patients at hospital discharge may allow more effective triage to manage-
ment strategies.
Background Heart failure severity at presentation predicts outcomes, but the prognostic importance of clinical status
changes due to interventions is less well described.
Methods Predictive models using variables obtained during hospitalization were created using data from the ESCAPE (Evalua-
tion Study of Congestive Heart Failure and Pulmonary Artery Catheterization Effectiveness) trial and internally vali-
dated by the bootstrapping method. Model coefficients were converted to an additive risk score. Additionally, data
from FIRST (Flolan International Randomized Survival Trial) was used to externally validate this model.
Results Patients discharged with complete data (n  423) had 6-month mortality and death and rehospitalization rates
of 18.7% and 64%, respectively. Discharge risk factors for mortality included BNP, per doubling (hazard ratio
[HR]: 1.42, 95% confidence interval [CI]: 1.15 to 1.75), cardiopulmonary resuscitation or mechanical ventilation
during hospitalization (HR: 2.54, 95% CI: 1.12 to 5.78), blood urea nitrogen, per 20-U increase (HR: 1.22, 95%
CI: 0.96 to 1.55), serum sodium, per unit increase (HR: 0.93, 95% CI: 0.87 to 0.99), age 70 years (HR: 1.05,
95% CI: 0.51 to 2.17), daily loop diuretic, furosemide equivalents 240 mg (HR: 1.49, 95% CI: 0.68 to 3.26),
lack of beta-blocker (HR: 1.28, 95% CI: 0.68 to 2.41), and 6-min walk, per 100-foot increase (HR: 0.955, 95%
CI: 0.99 to 1.00; c-index 0.76). A simplified discharge score discriminated mortality risk from 5% (score  0) to
94% (score  8). Bootstrap validation demonstrated good internal validation of the model (c-index 0.78, 95% CI:
0.68 to 0.83).
Conclusions The ESCAPE study discharge risk model and score refine risk assessment after in-hospital therapy for advanced
decompensated systolic HF, allowing clinicians to focus surveillance and triage for early life-saving interventions
in this high-risk population. (Evaluation Study of Congestive Heart Failure and Pulmonary Artery Catheterization
Effectiveness [ESCAPE]; NCT00000619) (J Am Coll Cardiol 2010;55:872–8) © 2010 by the American College
of Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.08.083l
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ccepted August 25, 2009.ation at highest risk of adverse events. The vast majority of
he systolic HF population consists of clinically stable
utpatients with mild to moderate symptoms who are
reated with neurohormonal antagonists and antitachycardia
lectrical therapies (1). The short-term risk for hospitaliza-
ion and death in these patients is relatively low. The
evelopment of clinical decompensation, which typically
ncludes the signs and symptoms of congestion, is the
rigger that brings this population to medical attention. In
act, 75% of HF admissions occur in patients with a
re-existent diagnosis (2). The adverse event risk likely
aries during an HF hospitalization depending on response
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March 2, 2010:872–8 The ESCAPE Risk Model and Discharge Scoreo therapy. However, there are currently no risk stratifica-
ion tools that triage patients after a period of relative
ecompensation, a vulnerable time in the natural history of
his disease when the short-term risks for rehospitalization
nd mortality are high (3,4).
Several risk stratification approaches in patients with HF
ave been established (5–11). However, few patients in
hese analyses had advanced functional limitations (New
ork Heart Association [NYHA] functional class IV symp-
oms), the cohort at highest risk of events (10). Addition-
lly, in-hospital mortality has been included in many prior
isk models and may limit the predictive accuracy in chronic,
mbulatory advanced HF. Thus, factors portending in-
reased risk of recurrent events after discharge in patients
ith recent NYHA functional class IV symptoms who are
ischarged alive are currently less well known. Furthermore,
atients may be better characterized by clinical status after
ystematic optimization of therapy than at the time of
dmission from varied outpatient regimens.
Effective risk stratification also impacts decisions regard-
ng resource allocation such as high-level surveillance, early
ntensive disease management, or aggressive pursuit of
igh-risk interventions such as left ventricular (LV) assist
evices or cardiac transplantation (1). This is because
atients at high risk of events are most likely to derive
aximum clinical benefits from many of the newer
esource-intensive strategies.
Using the unique population of the North American
SCAPE (Evaluation Study of Congestive Heart Failure
nd Pulmonary Artery Catheterization Effectiveness) trial
12), we provide a comprehensive analysis of the relation-
hips between discharge clinical factors and 6-month mor-
ality after optimization of therapy during a hospitalization
or patients with severe advanced HF. The aim of this
nvestigation was to develop a model and risk score using
atient data routinely available at discharge that would be
linically useful in triage decisions for patients with recent
F decompensation requiring hospitalization. Further, us-
ng these identifiers, the goal of this analysis was to create a
imple risk score based on discharge variables that could be
sed as an initial screen to identify patients at high and low
isk of recurrent events.
ethods
atient population. The ESCAPE trial enrolled 433 pa-
ients hospitalized with advanced HF at 26 sites in the U.S.
nd Canada between January 2000 and November 2003.
he design, primary end points, and results of the ESCAPE
rial have been previously published (12). Briefly, patients
ospitalized with severe symptomatic HF despite recom-
ended therapies were randomly assigned to receive clinical
ssessment or pulmonary artery catheter (PAC)-guided
herapy. Patients met the following inclusion criteria within
he past year: 1) an urgent visit to the emergency depart-
ent; 2) treatment during the proceeding month with t160 mg of furosemide daily;
) therapy with an angiotensin-
onverting enzyme (ACE) in-
ibitor and diuretic for at least
months; 4) LV ejection frac-
ion of 0.30%; 5) systolic blood
ressure of 125 mm Hg; and
) at least 1 sign and 1 symptom
f congestion. The exclusion
riteria included the following:
) serum creatinine 3.5 mg/dl;
) prior use of dobutamine or do-
amine 3 g/kg/min; or 3) any
rior use of milrinone during the
urrent hospitalization. The ther-
peutic target in both groups was resolution of clinical symp-
oms and signs of congestion (orthopnea, edema, and jugular
enous pressure elevation) with the additional goals in the
AC group of achieving a pulmonary capillary wedge pressure
f 15 mm Hg and a right atrial pressure of 8 mm Hg.
edication use was not specified, but use of intravenous
notropic agents was discouraged. The ACE inhibitor and
eta-blocker doses were titrated in the outpatient HF pro-
rams at these selected centers during the 6 months after
andomization according to patient tolerability and current
uidelines (1). Diuretics were adjusted both during and after
ospitalization to optimize fluid balance without progressive
eterioration in renal function.
ata collection and definitions. Selected demographics,
aseline characteristics, laboratory values, quality of life
ndices, and physiologic parameters were collected at base-
ine and throughout the hospitalization as well as at several
ime periods during follow-up using standard data collec-
ion forms. Specific instructions and definitions for all
ariables were provided to the investigative sites to assist
ith form completion. Clinical variables used in the trial
ere defined in the Manual of Operations. The survival
tatus of each patient was determined. The all-cause mor-
ality and recurrent hospitalization data were ascertained by
he site investigators.
tatistical methods. The baseline characteristics of the
tudy patients were summarized as frequencies and percent-
ges for categorical variables and by the median of the 25th
nd 75th percentiles for continuous variables.
During the conduct of the ESCAPE trial, B-type natri-
retic peptide (BNP) levels were measured using 2 distinct
ssays (Shinogi, Osaka, Japan, and Biosite, San Diego, Cali-
ornia). While BNP assays were available for nearly everyone,
nly data from patients in whom BNP levels were measured by
he Shinogi assay and with no missing variables (n 255) were
sed for mortality modeling in this analysis (Table 2).
Using Cox proportional hazards method, a model was
reated that was derived from a group of univariately
redictive discharge variables. The end point was time to
eath at 6 months. A bootstrapping method was then used
Abbreviations
and Acronyms
ACE  angiotensin-
converting enzyme
BNP  B-type natriuretic
peptide
BUN  blood urea nitrogen
HF  heart failure
LV  left ventricular
NYHA  New York Heart
Association
PAC  pulmonary artery
cathetero determine which variables would be included in the
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The ESCAPE Risk Model and Discharge Score March 2, 2010:872–8odel. The data were resampled 1,000 times, fitting a Cox
roportional hazards model that selected variables in a
tepwise manner. The baseline data were initially evaluated
o determine whether or not a nonlinear form of the variable
ould provide better predictability. The following variables
ere used as linear terms, unless otherwise indicated. The
andidate baseline clinical predictor variables were age (0 if
ge 65 years,  age-65 if age 65 years), systolic blood
ressure (SBP [0 if SBP 120 mm Hg,  120-SBP
therwise), blood urea nitrogen (BUN), 6-min walk (feet),
erum sodium, hemoglobin, creatinine, and ischemic etiol-
gy (yes/no). As the discharge model included events and/or
lterations in clinical parameters that occurred during the
ospitalization, additional variables were found to be rele-
ant and also included in the model: cardiopulmonary
esuscitation or mechanical ventilation (1 if the patient
equired, 0 otherwise), beta-blocker use at discharge, ACE
nhibitor use at discharge, high diuretic dose (1 if patient
as treated with diuretic doses equivalent to furosemide
240 mg/day, 0 otherwise). Loop diuretic equivalents were
alculated as follows: 1 mg furosemide  0.5 mg
orsemide  0.025 mg bumetanide. Only variables with a
value 0.10 were included, and those with a p value 
.05 remained in the model. The frequency with which each
ariable fit in the final model was determined, and those
ariables that remained in 50% of the 1,000 final models
ere included.
We also constructed a simplified score model for mortal-
ty based on discharge data. For this model, the significance
evels of the variables were ignored. A multivariable model
as constructed based on dichotomized measures (BNP,
UN 40 mg/dl) so that the estimated regression coeffi-
ients were similar, or were simple multiples of each other.
his score included 8 clinical variables with scores of 1 point
ossible for each, except for BUN and BNP, to which
dditional points were assigned for the highest values. A
aximum of 13 points was possible.
Finally, we used the data from FIRST (Flolan Inter-
ational Randomized Survival Trial) to externally vali-
ate the ESCAPE study 6-month mortality model de-
eloped in this study (13). Details of the FIRST study
ave been previously published (13). Briefly, this trial
valuated the effects of epoprostenol (Flolan) in patients
ith NYHA functional class IIIb/IV HF and decreased
V ejection fraction. Patients were eligible for enroll-
ent if severely compromised hemodynamics were doc-
mented while the patient was receiving a regimen of
igoxin, diuretics, and an ACE inhibitor. Patients were
andomly assigned to receive epoprostenol infusion or
tandard care. The trial was terminated early because of a
trong trend toward decreased survival among the pa-
ients treated with epoprostenol. Chronic intravenous
poprostenol therapy was not associated with improve-
ent in distance walked, quality of life, or morbid events.
f the variables in the ESCAPE model, 2 (diuretic dosend BNP levels) were not available in the FIRST study
l
iataset. The ESCAPE model for 6-month mortality was
edeveloped in the absence of these 2 variables, and the
ew ESCAPE model (without diuretic dose and BNP
evel) was validated in the FIRST study dataset. All
nalyses were performed using SAS statistical software
SAS Institute, Cary, North Carolina).
esults
mong 433 patients enrolled in the ESCAPE trial, 18.7%
ied and 64% had death or rehospitalization at 6-month
ollow-up. The baseline demographics and clinical charac-
eristics of patients enrolled in the ESCAPE trial stratified
y the outcome of a 6-month death are shown in Table 1.
atients who died were more likely to be older, have
revious coronary disease (prior myocardial infarction or
rior coronary revascularization), and lower systolic and
iastolic blood pressure. Additionally, BUN, serum creati-
aseline Clinical CharacteristicsTable 1 Baseline Clinical Characteristics
Death
p ValueNo (n  338) Yes (n  83)
Age, yrs 56 (46, 65) 60 (50, 74) 0.010*
Females 91 (27) 19 (23) 0.454
Race, nonwhite 133 (39) 35 (42) 0.638
Weight, kg 85 (71, 99) 80 (66, 93) 0.130*
Etiology
Ischemic 159 (47) 54 (65) 0.003
Nonischemic 177 (53) 29 (35) 0.004
Hypertension 165 (49) 34 (41) 0.183
Diabetes mellitus 108 (33) 29 (36) 0.526
Current smoking 41 (14) 11 (15) 0.798
Prior MI 138 (41) 49 (59) 0.003
Prior stroke 31 (9.2) 9 (11) 0.653
Prior PCI 74 (22) 24 (29) 0.184
Prior CABG 92 (27) 30 (36) 0.116
Heart rate, beats/min 81 (70, 91) 80 (71, 94) 0.342*
Blood pressure, mm Hg
Systolic 105 (94, 117) 99 (90, 113) 0.016*
Diastolic 68 (60, 74) 62 (60, 70) 0.019*
LVEF, % 20 (15, 25) 19 (15, 25) 0.297*
Serum sodium, mEq/l 137 (135, 140) 136 (132, 138) 0.001*
BUN, mg/dl 27 (19, 38) 41 (24, 65) 0.001*
Serum creatinine, mg/dl 1.3 (1.0, 1.7) 1.7 (1.3, 2.3) 0.001*
Baseline BNP, pg/mmol 518 (194, 1,052) 994 (371, 1,579) 0.001*
Peak VO2 9.9 (8.1, 11.7) 8.9 (7.0, 10.2) 0.080*
6-min walk, feet 367 (0, 792) 121 (0, 532) 0.011*
Any ACEI at baseline 270 (79.9) 60 (72.3) 0.132
Received beta-blocker at
baseline
220 (65.3) 43 (51.8) 0.023
Base angiotensin II
antagonist drugs
59 (17.5) 16 (19.3) 0.698
Diuretic at baseline
240 mg
111 (32.8) 43 (51.8) 0.001
alues are median (25th, 75th percentile) or n (%). *The p value is based on nonparametric test.
ACEI angiotensin-converting enzyme inhibitor; BNP B-type natriuretic peptide; BUN blood
rea nitrogen; CABG coronary artery bypass graft surgery; CHF congestive heart failure; LVEF
eft ventricular ejection fraction; MI  myocardial infarction; PCI  percutaneous coronary
ntervention; VO2  oxygen consumption.
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March 2, 2010:872–8 The ESCAPE Risk Model and Discharge Scoreine, and BNP were significantly higher in patients who
ied compared with patients who did not. Finally, the
edian 6-min walk distance was significantly shorter with a
trong trend toward lower peak volume of oxygen consump-
ion in patients who died.
Variables associated with 6-month mortality in patients
ith advanced HF discharged from the hospital in descend-
ng order of their model chi-square values are shown in
able 2. The strongest association with death was higher
ischarge BNP levels. The model c-index was 0.76, sug-
esting reasonably good ability of the model to discriminate
etween patients who died and 6-month survivors. Further-
ore, bootstrap methods demonstrated good internal vali-
ation of the model (c-index 0.78, 95% confidence interval:
.68 to 0.83).
This model was validated externally in the FIRST study
ataset. Because the FIRST study did not have information
n diuretic dose and BNP level, a new ESCAPE study
odel was developed without these 2 factors (c-index 0.74).
his new ESCAPE model (without diuretic dose and BNP
evel) showed modest discriminatory ability to identify
atients who died compared with those who survived
c-index 0.65).
Multivariate Discharge Predictors of Death in thTable 2 Multivariate Discharge Predictors o
Variables
Discharge BNP, per doubling 1
Cardiac arrest or mechanical ventilation, yes/no 2
Discharge BUN, per 20 mg/dl increase 1
Discharge sodium, per unit mEq/l increase 0
The c-index for this model is 0.758.
CI  confidence interval; HR  hazard ratio; other abbreviations as
Figure 1 Observed Versus Predicted Mortality for Score Model
Sample size is given in parentheses.Figure 1 shows the reliability of the model predictions for
-month mortality. The model was reasonably accurate in
stimation of events among patients at varying risks.
isk score. The multivariable model for 6-month mortal-
ty was converted into a coefficient-based simple additive
isk score (Table 3). This score included 8 clinical variables
ith scores of 1 point possible for each, except for BUN and
NP, to which additional points were assigned for the
ighest values. A maximum of 13 points was possible.
he summation of points assigned for each predictor led
o the prediction of overall 6-month mortality risk. The
se of categorized measures (rather than of continuous
easures) for the ease of calculating the score resulted in
dditional variables, which were not significant in the
riginal model (Table 2) to be included in the risk score
age 70 years, discharge 6-min walk test, diuretic dose
easures 240 mg/day, and no beta-blocker therapy).
able 4 demonstrates estimated probability of dying within
months of hospitalization based on the discharge score
odel. The majority of patients had a risk score 5. As
hown, the simplified discharge score allowed discrimina-
ion of the wide gradient of risks (5% risk of death with
core  0, to 94% with score  8).
CAPE Trialth in the ESCAPE Trial
95% CI Chi-Square p Value
1.174–1.689 13.57 0.0002
1.225–6.197 6.00 0.0143
1.044–1.605 5.65 0.0175
0.896–1.011 2.54 0.1113
e 1.e ESf Dea
HR
.408
.755
.295
.952
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espite advances in the management of advanced acute
ecompensated HF, patients have a very high risk of
ortality and rehospitalization during the early period after
ospitalization. In the ESCAPE trial, 1 of every 5 patients
ied, and two-thirds reached the combined end point of
eath or rehospitalization at 6 months despite a relatively
oung median age (60 years). Risk stratification using
linical and laboratory information at the time of discharge
ay allow more precise risk estimation, closer follow-up of
he high-risk group, and timely allocation of limited re-
ources of advanced device therapies (including LV assist
evices) and cardiac transplantation before patients have
eteriorated to become ineligible.
The clinical determinants of cardiac events and mortality
n patients with severe advanced decompensated HF due to
ystolic dysfunction are complex. Nonetheless, as shown in
ur study, much of the important prognostic information
s contained in the clinical characteristics representative
implified Discharge Score Modelf Mortality From the ESCAPE StudyTable 3 Simplifi d Discharg Score Modelof Mortality From the ESCAPE Study
Criteria (On Basis of Discharge Measurements)
Score if Yes
(No  0)
Age 70 yrs 1
BUN 40 mg/dl 1
BUN 90 mg/dl* 1
6-min walk 300 feet 1
Sodium 130 mEq/l 1
CPR/mechanical ventilation, yes/no 2
Diuretic dose 240 mg at discharge, yes/no 1
No beta-blocker at discharge 1
Discharge BNP 500 pg/mmol 1
Discharge BNP 1,300 pg/mmol 3
Total of column 2 (score)
his model includes terms which are not statistically significant. However, all terms in the model
ave approximately the same estimated effect (except for assist which has about twice the effect).
his model has a c-index of 0.739, which is comparable to the continuous multivariate models.
iuretic dose is represented in furosemide equivalents. *If the BUN level is 90 mg/dl then both
UN variables are coded as 1.
CPR  cardiopulmonary resuscitation; other abbreviations as in Table 1.
Estimated Probability of Dying in 6 Months on BTable 4 Estimated Probability of Dying in 6
Score
No. of
Patients
Observed
Deaths
0 91 7
1 125 13
2 114 19
3 53 14
4 29 13
5 15 12
6 4 3
7 1 1
8 1 1
The estimated probabilities for death with and without BNP are show
points for BNP 1,300 pg/mmol.
BNP  B-type natriuretic peptide.f the severity of LV dysfunction. After age, these include
irculatory-renal compromise as indicated by hypotension,
levated natriuretic peptide levels, high BUN levels, and the
eed for high doses of diuretics to maintain a normal
olume status. Clinical instability defined by cardiac arrest,
he need for mechanical ventilation, intolerance to beta-
locker therapy, and significant functional limitations, de-
ned in this analysis by a short 6-min walk distance, were
lso adverse prognostic factors. Taken together, these vari-
bles were nearly complete in explaining 76% of variation in
he incidence of death at 6-month follow-up and were
eliable in accurately differentiating various risk categories.
e further developed a simple bedside risk prediction score
hat can be used to accurately estimate the probability of
eath for patients with NYHA functional class IV HF. This
ischarge risk score encompasses a wide range of risks in
his advanced HF population, making this tool valuable for
linical decision making and patient counseling. Further-
ore, the ESCAPE study model is equally predictive as the
idely validated hospitalization heart failure risk models of
he ADHERE (Acute Decompensated Heart Failure Na-
ional Registry) study (2) and the EFFECT (Enhanced
eedback for Effective Cardiac Treatment) study (14), as
hown in Table 5.
The ESCAPE risk score extends the existing literature
valuating risk factors for death in patients presenting with
mbulatory HF into the spectrum of advanced decompensated
isease. The major independent risk factors for death in most
f these studies are nonetheless similar and include older age
9–11,14–17), chronic lung or liver disease (14), depression
18), NYHA functional class IV (16), higher heart rate
6,15,17), lower systolic blood pressure (6,9–11,14–17,19),
ower LV ejection fraction (9–11,15), lower serum sodium
6,11,14–17), higher BUN or creatinine (2,11,14–17), lack of
eta-blocker use (11,20,21), and requirement of high diuretic
ose (equal to 240 mg of furosemide) (11,22,23).
While these studies and registries demonstrate the consis-
ency of many of the important variables, they were limited in
heir inclusion of patients with advanced systolic dysfunction
of Discharge Score Modelhs on Basis of Discharge Score Model
Observed
Mortality
Estimated Probability of Dying
No BNP With BNP
0.077 0.053 0.033
0.104 0.103 0.065
0.167 0.189 0.123
0.264 0.322 0.223
0.448 0.492 0.368
0.800 0.664 0.543
0.750 0.801 0.708
1.000 0.891 0.831
1.000 0.943 0.909
is model, 1 point is added for BNP 500 pg/mmol and 3 additionalasisMont
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March 2, 2010:872–8 The ESCAPE Risk Model and Discharge Scorend severe decompensation. The ESCAPE trial captured this
mportant population and characterized the clinical, laboratory,
hysiologic, and functional status of these patients.
Relative systemic hypotension as well as high BUN and
igh doses of loop diuretics are all markers of significantly
educed LV systolic function associated with hemodynamic
ompromise. Previous studies and registries have demon-
trated the importance of renal dysfunction in predicting
utcome (24,25). In particular, BUN may not only be a
arker of advanced renal dysfunction but also may indicate
he combined deterioration of cardiac and renal function.
imilarly, a low systolic blood pressure may represent low
orward output. Thus, it is not surprising that it has been
hown to be associated with increased mortality consistently
n all previous studies (6–12,14–17). Increased requirement
or loop diuretics (i.e., 240 mg) suggests an important
opulation that is severely congested, resistant to diuretic
herapy, and has an increased risk of events at follow-up
22,23). The presence of respiratory failure requiring me-
hanical ventilation and cardiac arrest during an HF hospi-
alization signifies a tenuous clinical profile associated with
rolonged lengths of stay, concomitant increased morbidi-
ies, associated infections, cognitive impairment, and sub-
equently reduced clinical outcomes.
The finding that beta-blocker therapy influences outcome
s not novel and has previously been demonstrated in the
PTIMIZE-HF (Organized Program to Initiate Lifesav-
ng Treatment in Hospitalized Patients With Heart Failure)
tudy, the IMPACT-HF (Initiation Management Predis-
harge: Process for Assessment of Carvedilol Therapy in
eart Failure) registry and trial, and the ESCAPE study
21,26,27), and is consistent with benefits of these agents
hown in randomized clinical trials of advanced HF.
hether these agents improve survival or merely identify
atients with less decompensation who can tolerate beta-
lockade is not clear, but their use continues to be a
The ESCAPE, EFFECT, and ADHERE Studies MoTable 5 The ESCAPE, EFFECT, and ADHERE
Trial n (Derivation Cohort) P
ESCAPE 423 BNP
Cardiac arrest or m
Sodium level
EFFECT 2,624 Age
Systolic blood press
Respiratory rate
Sodium level
BUN
Comorbid condition
dementia, COPD
ADHERE 33,046 BUN
Systolic blood press
Age
Heart rate
Serum creatinine
*Area under the receiver-operating characteristic curve.
COPD  chronic obstructive pulmonary disease; other abbreviationavorable factor in the overall risk assessment. oThe natural history of HF challenges all models of risk
etermination. Typically, HF patients experience prolonged
eriods of stability interrupted by acute events that result in
olume overload or reduced perfusion with associated end-
rgan dysfunction. Further, disease progression is common
ver a variable period of time that is patient-specific. Thus,
he risk of adverse events, hospitalization, and death fluc-
uates but tends to be highest during the period surrounding
hospitalization. Further, it should be anticipated that risks
hange during an HF hospitalization depending on re-
ponse to therapy. To date, the ESCAPE study risk model
s the only strategy that addresses hospitalized patients with
dvanced HF and accounts for alterations in clinical status,
hysiology, and functional status in the prediction of short-
nd intermediate-term risk.
linical importance of risk stratification. Patients with
dvanced HF consume considerable resources and have a
igh risk of morbidity and mortality. Rapid advances in
reatment strategies have resulted in several new therapeutic
ptions available to clinicians managing these patients.
owever, the major limitations in ubiquitous use of these
ewer technologies include lack of widespread availability
nd prohibitive cost. The ability to identify the high-risk
ubgroups should allow better resource use by targeting the
ntensive strategies to patients at particularly high risk.
owever, this hypothesis remains to be tested because it is
lso possible that these patients may have advanced beyond
he benefit of our current strategies. Prospective experience
ill be required to determine whether such a focused risk-
ased strategy of resource allocation (i.e., implantable
ardioverter-defibrillators, LV assist devices, cardiac transplan-
ation, cellular regeneration) is an effective use of limited
esources to improve overall outcomes.
tudy limitations. The ESCAPE study population does
ot represent the general population of hospitalized HF
atients, but rather patients with severe LV dysfunction and
dvanced symptoms. The study population was composed
omparisonies Model Comparison
ors End Points C-Index
ical ventilation
6-month mortality 0.76
brovascular disease,
ic cirrhosis, cancer
30-day mortality
1-yr mortality
0.8
0.77
In-hospital mortality 0.759*
Table 1.del CStud
redict
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uref patients at centers with expertise and extensive experience
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rom which most patients are currently selected for ad-
anced management strategies and replacement therapies.
dditionally, patients who had baseline characteristics
hown to be associated with worse outcomes were excluded,
uch as those with severe renal dysfunction (creatinine 3.5
g/dl) or those requiring high doses of inotropes during
ospitalization. Although our model was internally vali-
ated using the bootstrap method, we were unable to find a
ataset that had all the elements available in the ESCAPE
tudy dataset for external validation. As a result, as discussed
n the preceding text, we validated the “reduced” ESCAPE
odel (without diuretic dose and BNP level) in the FIRST
tudy data. We support further external validation in the future
o further confirm the predictive accuracy and reliability of the
SCAPE study model before broad adoption for clinical use.
onclusions
his model and risk score for advanced decompensated HF
atients, developed from easily determined clinical character-
stics and hospital course characteristics, can be used to identify
atient cohorts with high, medium, or low risk for death at 6
onths. Thus, this risk score allows clinicians to intensify
onitoring follow-up and therapeutic strategies. The mortality
odel provides a high degree of discriminatory power using
he clinical variables. Prospective validation of the models in
ndependent databases and using the model to triage risk, in
oth clinical practice and in clinical trials, should improve the
are of these patients with advanced HF.
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